According to the research report titled ‘Global Multiple Sclerosis (MS) Market - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline, and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global multiple sclerosis market was worth USD 26.01 billion in the year 2020 and is expected to observe robust growth through 2026.

Growing awareness regarding disease-modifying drugs as a treatment option, technological breakthroughs, shifting preferences towards consuming oral drugs, and an increase in the number of pipeline drugs are some of the major factors driving the growth of the global multiple sclerosis market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489504/  

This market growth can also be credited to supportive regulatory as well as positive outlook from both government and non-government organizations. Several pharmaceutical companies are conducting clinical studies to develop effective and innovative therapies for treating immunity disorders as well as creating novel drugs in multiple sclerosis radiology for patients suffering from the condition.

The market is fragmented in terms of drug class, route of administration, distribution channel and regional contribution.

Based on drug class, the market is further divided into immunosuppressants, immunomodulators, interferons, and others). Moving on to the route of administration, this business space is divided into oral, injectable, and intravenous segments.

As per the distribution channel, the market is segmented into hospital, retail, and online pharmacy.

The geographical analysis of this business space extends to the Middle East & Africa, Latin America, Asia-Pacific, North America, and Europe, with major emphasis on countries such as China, India, Japan, South Korea, France, the U.K., Germany, U.S., Italy, and Canada.

The leading companies operating in the global multiple sclerosis market include Bristol-Myers Squibb, Pfizer Inc., Novartis AG, Bayer AG, EMD Serono Inc., F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc, Teva Pharmaceuticals Industries Limited, Biogen Inc., and NervGen Pharma.